0000000000910398

AUTHOR

Ainhoa Fernandez Yunquera

showing 1 related works from this author

Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation:A Retrospective Study

2021

Background and aim Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared to best supportive care (BSC) in LT-patients after sorafenib discontinuation. Methods This observational multicenter retrospective study included LT-patients with HCC-recurrence who discontinued first-line sorafenib. Group-1 was constituted by regorafenib-treated patients, while control group was selected among patients treated with best supportive care (BSC) due to unavailability of second-line options at the time of sorafenib discontinuation and who were sorafenib-tolerant prog…

OncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularPyridinesmedicine.medical_treatmentAntineoplastic AgentsLiver transplantationchemistry.chemical_compoundRegorafenibInternal medicineClinical endpointmedicineHumansRetrospective StudiesTransplantationHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsRetrospective cohort studySorafenibmedicine.diseaseRecurrent Hepatocellular Carcinomadigestive system diseasesLiver TransplantationDiscontinuationchemistryHepatocellular carcinomaSurgerybusinessmedicine.drug
researchProduct